<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774787</url>
  </required_header>
  <id_info>
    <org_study_id>08US02IMIQ-Rigel</org_study_id>
    <nct_id>NCT00774787</nct_id>
  </id_info>
  <brief_title>Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses</brief_title>
  <official_title>A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigel Dermatology</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if use of topical imiquimod cream after
      cryotherapy of actinic keratoses reduces the total number of lesions (those treated with
      cryotherapy and new ones) at follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratoses are common skin lesions associated with excess sun exposure. Over time,
      there is a small risk a lesion may progress to skin cancer. Since one can not predict which
      actinic keratosis will progress, the standard of care is to treat the lesions. The most
      commonly used method to treat actinic keratoses in the United States is with cryotherapy,
      which uses intense cold to freeze and destroy the lesions. Efficacy appears to be related to
      how long one freezes the lesion, but increasing the freeze time may result in increased pain
      and/or skin pigment changes after treatment.

      Cryotherapy is a provider-administered &quot;focal&quot; treatment that only treats the lesions that
      are frozen. There may be early actinic keratoses in the skin surrounding treated lesions
      that are not easily seen; these may progress over time to visible lesions. There several
      patient-administered topical treatments for actinic keratoses that are applied to a
      treatment area or &quot;field&quot; rather than to specific lesions. Imiquimod 5% cream is one such
      treatment, and is approved in the United States for the treatment of AKs with a dosing
      regimen of 1 packet applied 2 times per week to a 25 cm2 area 2x/week for 16 weeks.

      The study will use a split-face design (one side of face treated and the other side
      untreated) to explore whether a 4-week course of topical imiquimod 5% cream after
      cryotherapy of actinic keratoses reduces the total number of lesions (those treated with
      cryotherapy and new ones) in the treatment area at follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Actinic Keratoses Count at 4-8 Weeks Post-treatment</measure>
    <time_frame>Baseline, 4-8 weeks post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change = [(actinic keratoses count at 4-8 weeks post-treatment)-(actinic keratoses count at baseline)]/(actinic keratoses count at baseline)]*100%. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses. Actinic keratoses at 4-8 weeks post-treatment visit includes all actinic keratoses in each respective treatment area, baseline and new.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Appearance Score at 4-8 Weeks Post-treatment</measure>
    <time_frame>4-8 weeks post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cosmetic appearance score, based recall comparison to appearance at baseline. Seven point scale: +3 = treatment area is much better appearing; +2 = treatment area is moderately better appearing; + 1 = treatment area is slightly better appearing; 0 = treatment area appears same; -1 = treatment area is slightly worse appearing; -2 = treatment area is moderately worse appearing; -3 = treatment area is much worse appearing. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Imiquimod, treatment, topical cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control, Untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment of treatment area on the other half of the face and/or balding scalp</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod 5% cream</intervention_name>
    <description>1 packet (250 mg cream) 3 times per week for 4 weeks</description>
    <arm_group_label>Imiquimod, treatment, topical cream</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Untreated</intervention_name>
    <description>No treatment of control side</description>
    <arm_group_label>Control, Untreated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of actinic keratoses

          -  Actinic keratoses in two reasonably bilaterally symmetric areas on the face and/or
             balding scalp:

               -  each area with a minimum of 25 cm^2 and a maximum of 50 cm^2

               -  each area with at least 6 typical, non-hypertrophic target AKs

               -  with target AK lesion counts of +/- 1 lesion between the areas

               -  each area that the patient can distinguish with respect to study drug
                  application

          -  Able to comply with all study requirements

          -  Are willing and able to give written informed consent

        Exclusion Criteria:

          -  Uncontrolled intercurrent or chronic illness

          -  Systemic immunocompromise due to disease or treatment

          -  Clinically relevant systemic autoimmune disease

          -  Pregnant or nursing

          -  Dermatologic disease and/or condition in the treatment area that may be exacerbated
             by imiquimod or cause difficulty with examination

          -  Participation in another clinical study

          -  Allergies to imiquimod or any of the excipients in the cream

          -  Treatment within the past 90 days with any of the following:

               -  Psoralens plus ultraviolet A therapy

               -  Ultraviolet B therapy

               -  Systemic immunomodulators (e.g. oral or parenteral corticosteroids at greater
                  than physiologic doses, interferons, anti-TNF agents, cytokines)

               -  Chemotherapeutic or cytotoxic agents;

               -  Investigational agent

          -  Treatment within the past 30 days with any of the following:

               -  Surgical excision

               -  Photodynamic therapy

               -  Curettage

               -  Topical corticosteroids

               -  Laser

               -  Dermabrasion

               -  Chemical peel

               -  Imiquimod 5% cream

               -  Topical retinoids

               -  5-fluorouracil

               -  Masoprocol

               -  Pimecrolimus or tacrolimus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell S Rigel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigel Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Q Del Rosso, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Spencer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spencer Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spencer Dermatology and Skin Surgery</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Del Rosso</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigel Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 1, 2010</lastchanged_date>
  <firstreceived_date>October 16, 2008</firstreceived_date>
  <firstreceived_results_date>September 30, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Darrell S. Rigel</name_title>
    <organization>Rigell Dermatology</organization>
  </responsible_party>
  <keyword>Combination treatment</keyword>
  <keyword>Imiquimod</keyword>
  <keyword>Cryotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled - 08 Oct 08; last patient enrolled - 07 Jul 09; last patient completed: 09 Sep 09; Setting - private practice clinics</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
          <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
          <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.8" spread="9.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participant</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Actinic keratoses, total</title>
          <description>Total count of clinically diagnosed actinic keratoses in target treatment area</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17.3" spread="4.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Actinic keratoses, Imiquimod side</title>
          <description>Count of actinic keratoses on side of target treatment area randomly assigned to imiquimod 5% cream following cryotherapy</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.7" spread="2.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Actinic keratoses, Observation Side</title>
          <description>Count of actinic keratoses on side of target treatment area randomly assigned to observation following cryotherapy</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.5" spread="2.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Actinic Keratoses Count at 4-8 Weeks Post-treatment</title>
        <description>Percent change = [(actinic keratoses count at 4-8 weeks post-treatment)-(actinic keratoses count at baseline)]/(actinic keratoses count at baseline)]*100%. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses. Actinic keratoses at 4-8 weeks post-treatment visit includes all actinic keratoses in each respective treatment area, baseline and new.</description>
        <time_frame>Baseline, 4-8 weeks post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients who had end of study visit with count of actinic keratoses. Change not calculated for one patient who was lost to follow-up immediately after baseline visit, and had no post-treatment data. Actinic keratoses at 4-8 weeks post-treatment visit includes all actinic keratoses in each respective treatment area, baseline or new.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
            <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Actinic Keratoses Count at 4-8 Weeks Post-treatment</title>
            <description>Percent change = [(actinic keratoses count at 4-8 weeks post-treatment)-(actinic keratoses count at baseline)]/(actinic keratoses count at baseline)]*100%. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses. Actinic keratoses at 4-8 weeks post-treatment visit includes all actinic keratoses in each respective treatment area, baseline and new.</description>
            <units>Percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Change from baseline, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-73.2" spread="27.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from baseline, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-62.0" spread="30.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Complete Clearance of Actinic Keratoses at 4-8 Weeks Post-treatment</title>
        <description>Complete clearance (actinic keratosis count of 0) in each respective area at 4-8 weeks post-treatment. Actinic keratoses at 4-8 weeks post-treatment visit includes all actinic keratoses in each respective treatment area, baseline and new.</description>
        <time_frame>4-8 weeks post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
            <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Treatment areas analyzed</title>
            <units>Treatment areas</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Complete Clearance of Actinic Keratoses at 4-8 Weeks Post-treatment</title>
            <description>Complete clearance (actinic keratosis count of 0) in each respective area at 4-8 weeks post-treatment. Actinic keratoses at 4-8 weeks post-treatment visit includes all actinic keratoses in each respective treatment area, baseline and new.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Completely cleared, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Completely cleared, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Appearance Score at 4-8 Weeks Post-treatment</title>
        <description>Cosmetic appearance score, based recall comparison to appearance at baseline. Seven point scale: +3 = treatment area is much better appearing; +2 = treatment area is moderately better appearing; + 1 = treatment area is slightly better appearing; 0 = treatment area appears same; -1 = treatment area is slightly worse appearing; -2 = treatment area is moderately worse appearing; -3 = treatment area is much worse appearing. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses.</description>
        <time_frame>4-8 weeks post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients who had end of study visit with cosmetic appearance assessment. Cosmetic appearance score, by treatment area, not included for one patient who was lost to follow-up immediately after baseline visit, and had no post-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
            <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cosmetic Appearance Score at 4-8 Weeks Post-treatment</title>
            <description>Cosmetic appearance score, based recall comparison to appearance at baseline. Seven point scale: +3 = treatment area is much better appearing; +2 = treatment area is moderately better appearing; + 1 = treatment area is slightly better appearing; 0 = treatment area appears same; -1 = treatment area is slightly worse appearing; -2 = treatment area is moderately worse appearing; -3 = treatment area is much worse appearing. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Investigator assessed, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" spread="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Investigator assessed, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patient assessed, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" spread="1.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patient assessed, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Local Skin Reactions</title>
        <description>Mean maximum post-baseline intensity of investigator assessed local skin reactions (erythema, edema, weeping/exudate, flaking/scaling/dryness, scabbing/crusting, erosion/ulceration) by treatment area. 0 = none, 1 = mild, 2 = moderate, 3 = severe. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses.</description>
        <time_frame>Post baseline to end of study (4-8 weeks post-treatment)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>One patient not included who was lost to follow-up immediately after baseline visit, and had no post-treatment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
            <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Local Skin Reactions</title>
            <description>Mean maximum post-baseline intensity of investigator assessed local skin reactions (erythema, edema, weeping/exudate, flaking/scaling/dryness, scabbing/crusting, erosion/ulceration) by treatment area. 0 = none, 1 = mild, 2 = moderate, 3 = severe. Data from one patient, lost to follow-up immediately after cryotherapy, not included in these analyses.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Erythema, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2" spread="0.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="0.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weeping/exudate, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weeping/exudate, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flaking/scaling/dryness, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flaking/scaling/dryness, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Scabbing/crusting, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" spread="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Scabbing/crusting, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erosion/ulceration, imiquimod side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erosion/ulceration, observation side</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="0.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8-12 weeks: from baseline cryotherapy visit to end of study (4-8 weeks post completion of imiquimod treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cryotherapy Followed by Imiquimod 5% Cream or Observation</title>
          <description>Split-face study of cryotherapy of all actinic keratoses in target treatment area (bilaterally symmetrical area on face or balding scalp) followed by random assignment to treatment of half of treatment area with imiquimod 5% cream and of other half to no treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic interferon reaction on areas with previous sun exposure; arms, thighs, upper chest, upper b</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PIs must agree on communication of complete results, but may discuss individual site results. Collaborator can review complete results communications prior to public release and can embargo communications regarding trial results, if patents are to be pursued, for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the collaborator for review. The collaborator cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label; small patient number; planned secondary endpoint of change in only lesions treated with cryotherapy (baseline) not determinable as only all lesions (baseline + new) consistently captured.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Darrell Rigel</name_or_title>
      <organization>Rigel Dermatology</organization>
      <phone>212-684-5964</phone>
      <email>dsrigel@prodigy.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
